In the Western world, LinkedIn is a staple for many recruitment professionals. It has proven to be a powerful tool for networking, talent sourcing and job postings. But in Japan, people don’t use LinkedIn very much.Here’s why LinkedIn isn’t popular…
BUSINESS
Tolvaptan Re-Submitted to US FDA for ADPKD: Otsuka
Otsuka Pharmaceutical said on November 5 that its vasopressin V2 receptor antagonist tolvaptan was re-submitted to the US FDA for the treatment of autosomal dominant polycystic kidney disease (ADPKD) four years after the regulator rejected the drug, requesting additional data.…
To read the full story
Related Article
- Otsuka’s Jynarque Earns FDA Nod for ADPKD at Second Attempt
April 26, 2018
- US FDA Requests Additional Data for Tolvaptan for Treatment of ADPKD: Otsuka
September 2, 2013
- US FDA Advisory Committee Votes Against Approval of Tolvaptan for Treatment of ADPKD
August 8, 2013
- FDA Accepts Otsuka Tolvaptan NDA for Priority Review
April 17, 2013
BUSINESS
- Majority of PNH Patients Expected to Switch to Novartis’ Fabhalta: Expert
August 30, 2024
- AstraZeneca Japan Launches Research on Lung Cancer Survival Rate Using National Registry
August 30, 2024
- JCR’s JR-441 Primed for Japan Clinical Trial in MPS IIIA
August 30, 2024
- Personal Info of Over 700,000 People Potentially Leaked: Sanofi Japan
August 29, 2024
- Sawai Nabs Distribution Rights to CureApp’s Alcoholism Therapy App
August 29, 2024
An increasing number of companies in Japan are showing an eagerness to snatch up “drug loss” assets. As of this…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…